Abstract 137P
Background
Multiple biomarkers are routinely being used to guide cancer treatment decisions. BRAF mutation has been identified in a wide range of solid tumors and multiple molecules targeting mutated tumors are available in the market or are under development. This study aims to describe BRAF test frequency and the prevalence of BRAF mutations in patients with solid tumors in France from 2015 to 2019.
Methods
This retrospective observational study in cancer patients retrieved data from Cancerology database, 2015, 2017 and 2019 editions. Cancerology is a real-world French database, which contains data collected from routine medical practice in cancer patients using fully anonymized case report forms (CRF). CRFs were filled by oncologists, hematologists and other specialists treating cancer. Data obtained from the forms was weighted and extrapolated to be representative of the cancer population in France. Descriptive analyses were performed for overall cancer population and by tumor type. Results were also described for each year.
Results
Out of 1,373,231 French patients with solid tumors from 2015 to 2019, 21.1% were tested for BRAF mutations. About 12.6% among them harbored BRAF mutations and 4.7% were waiting for test results at the time of data collection. The number of patients tested gradually increased over time, but also the proportion of non-mutated patients increased (78.2% in 2015, 81.5% in 2017 and 87.1% in 2019). In 2019, the tumor type groups with the highest proportions of tested patients were melanoma (84.7%), colorectal (64.9%) and non-small cell lung cancer (55.4%); and the ones with the highest mutation rates were melanoma (40.5%), colorectal (3.6%) and endocrine tumors (3.2%). In 2019, metastatic patients were more frequently tested when compared to non-metastatic patients (26.7% vs 6.8%, respectively), and the prevalence of BRAF mutation was similar in the both groups (9.4% vs 10.3%, respectively); about 2.7% of metastatic patients were waiting for test results (vs 5.0% for non-metastatic).
Conclusions
Although BRAF mutation test rates are consistently increasing over time, only few patients with solid tumors had BRAF mutations, mostly including tumors where test results may play an important role in the drug choice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kantar Health SAS.
Funding
Has not received any funding.
Disclosure
E. Manna: Shareholder/Stockholder/Stock options: Clinica Humanitas. K. Kikuchi: Full/Part-time employment: Kantar Health. H. Chalubert: Full/Part-time employment: Kantar Health. I. Amri: Full/Part-time employment: Kantar Health. P. Medina: Full/Part-time employment: Kantar Health.